Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
iCAD reports Q1 EPS (7c), consensus (12c) » 16:10
04/28/21
04/28
16:10
04/28/21
16:10
ICAD

iCAD

$17.79 /

-0.46 (-2.52%)

Reports Q1 revenue…

Reports Q1 revenue $8.64M, consensus $7.95M. "We are extremely pleased with the overall performance of our business in the first quarter," said Mike Klein, chairman and CEO. "Our first quarter total revenue of $8.6 million represented a 32 percent increase over our 2020 first quarter and we generated 34% year-over-year growth in AI product revenue in the first quarter, as we continue to drive further adoption of ProFound AI(R). Importantly, these impressive growth rates were achieved while we maintained our prudent operating expense management measures, which resulted in a 86% decline in net loss to $0.07 per share. We ended the quarter with $46.9 million in cash, and just applied approximately $7.4 million of that cash to repay our credit facility in full."

ShowHide Related Items >><<
ICAD iCAD
$17.79 /

-0.46 (-2.52%)

ICAD iCAD
$17.79 /

-0.46 (-2.52%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
ICAD iCAD
$17.79 /

-0.46 (-2.52%)

  • 03
    Mar
ICAD iCAD
$17.79 /

-0.46 (-2.52%)

Initiation
iCAD initiated with a Buy at Guggenheim » 11:15
04/22/21
04/22
11:15
04/22/21
11:15
ICAD

iCAD

$18.04 /

+0.18 (+1.01%)

Guggenheim analyst Chris…

Guggenheim analyst Chris Pasquale initiated coverage of iCAD with a Buy rating and $24 price target. Given its portfolio with "two relatively distinct businesses" for the detection and treatment of cancer, iCAD is a "unique asset within the small-cap MedTech universe," Pasquale tells investors. Though he sees "limited synergy" between the company's two segments, he sees each having the potential to drive significant growth and believes "investors are essentially getting the more speculative Therapy business for free at current levels," Pasquale said.

ShowHide Related Items >><<
ICAD iCAD
$18.04 /

+0.18 (+1.01%)

ICAD iCAD
$18.04 /

+0.18 (+1.01%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$18.04 /

+0.18 (+1.01%)

  • 03
    Mar
ICAD iCAD
$18.04 /

+0.18 (+1.01%)

Hot Stocks
iCAD presented new data for ProFound AI breast cancer detection » 08:17
04/19/21
04/19
08:17
04/19/21
08:17
ICAD

iCAD

$17.79 /

-0.73 (-3.94%)

iCAD announced that new…

iCAD announced that new research supporting the clinical value of ProFound AI for Digital Breast Tomosynthesis was presented at the Society of Breast Imaging Symposium, April 9-11, and at the National Consortium of Breast Centers Annual Interdisciplinary Breast Center Conference, April 16-19. Emily Conant, MD, Professor and Division Chief of Breast Imaging at the University of Pennsylvania Medical Center, presented findings from a retrospective analysis involving ProFound AI for DBT in a presentation titled "Feasibility of automated identification of low-likelihood of cancer cases in digital breast tomosynthesis screening," at the SBI Symposium. At the NCoBC Interdisciplinary Breast Center Conference, Mark Traill, MD, University of Michigan Health, presented findings from a study titled "Correlation between BI-RADS Assessment Categories and Artificial Intelligence Case Scores," which was a winner in the "Breast Disease Diagnosis and Management" category. According to study findings presented by Conant at the SBI Symposium, ProFound AI for DBT accurately identified 33.4% of normal screening DBT exams with no cancers being missed, based solely on the ProFound AI Case Score. When researchers also factored in breast density and age, ProFound AI identified 58.6% of normal cases with no false negatives. The study was conducted to evaluate the thresholds at which the ProFound AI system could be used for triaging DBT exams to reach a minimum rate of false negatives per 1,000 screened in an enriched dataset of 506 biopsy-proven cancer cases and 1,293 non-cancer cases with 320 days of negative follow-up. A consecutive series of cases were collected from 18 sites in the United States and three sites in France. In addition, new data presented by Mark Traill at the NCoBC Interdisciplinary Breast Center Conference highlights the comparison of ProFound AI Case Scores to BI-RADS assessment categories determined by a single radiologist without using AI in a retrospective analysis. Researchers used ProFound AI on 890 consecutive DBT studies and 50 consecutive cases with biopsy-proven breast cancer detected with DBT. Results showed a strong positive correlation between a ProFound AI Case Score of less than 60 percent and patients assessed as likely to be normal, while most of the biopsy-proven cancers had a Case Score of greater than 60%.

ShowHide Related Items >><<
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

ICAD iCAD
$17.79 /

-0.73 (-3.94%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

  • 03
    Mar
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 19:16
04/05/21
04/05
19:16
04/05/21
19:16
ICAD

iCAD

$19.96 /

+0.04 (+0.20%)

, ILMN

Illumina

$384.41 /

-0.72 (-0.19%)

, SPNE

SeaSpine

$17.93 /

+0.23 (+1.30%)

, DCT

Duck Creek Technologies

$44.50 /

-0.5 (-1.11%)

, GBOX

GreenBox

$15.36 /

+1.47 (+10.58%)

, OPNT

Opiant Pharmaceuticals

$11.15 /

+0.49 (+4.60%)

, MRVI

Maravai Lifesciences

$34.59 /

+0.4 (+1.17%)

, PSX

Phillips 66

$82.06 /

-1.08 (-1.30%)

, ARES

Ares Management

$59.12 /

+1.59 (+2.76%)

, TPTX

Turning Point Therapeutics

$89.91 /

-0.7 (-0.77%)

, UCTT

Ultra Clean

$64.92 /

+1.37 (+2.16%)

, USAT

Changed to CTLP

$12.77 /

+0.76 (+6.33%)

Check out this evening's…

ShowHide Related Items >><<
USAT Changed to CTLP
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

GBOX GreenBox
$15.36 /

+1.47 (+10.58%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ILMN Illumina
$384.41 /

-0.72 (-0.19%)

04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
03/31/21 Canaccord
Illumina upgraded to Buy from Hold at Canaccord
03/31/21 Atlantic Equities
Illumina downgraded to Neutral from Overweight at Atlantic Equities
SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

03/24/21 Canaccord
Canaccord likes what 7D acquisition brings to SeaSpine Holdings
03/02/21 Canaccord
SeaSpine price target raised to $25 from $23 at Canaccord
03/01/21 Piper Sandler
SeaSpine price target raised to $28 from $22 at Piper Sandler
01/29/21 Piper Sandler
SeaSpine price target raised to $22 from $18 at Piper Sandler
DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

01/13/21 Goldman Sachs
Sapiens initiated with a Neutral at Goldman Sachs
10/21/20 RBC Capital
Duck Creek Technologies price target raised to $51 from $45 at RBC Capital
10/21/20 Barclays
Duck Creek Technologies price target raised to $48 from $43 at Barclays
09/08/20 DA Davidson
Duck Creek Technologies initiated with a Buy at DA Davidson
GBOX GreenBox
$15.36 /

+1.47 (+10.58%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

03/03/21 Morgan Stanley
Maravai Lifesciences price target raised to $54 from $35 at Morgan Stanley
03/03/21 KeyBanc
Maravai Lifesciences price target raised to $46 from $39 at KeyBanc
03/03/21 Credit Suisse
Maravai Lifesciences price target raised to $42 from $34 at Credit Suisse
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

04/01/21
Fly Intel: Top five analyst downgrades
04/01/21 Piper Sandler
Phillips 66 downgraded to Neutral on valuation at Piper Sandler
04/01/21 Piper Sandler
Phillips 66 downgraded to Neutral from Overweight at Piper Sandler
03/17/21 Citi
Phillips 66 price target raised to $99 from $81 at Citi
ARES Ares Management
$59.12 /

+1.59 (+2.76%)

03/29/21
Fly Intel: Top five analyst downgrades
03/29/21 BMO Capital
Ares Management downgraded to Market Perform from Outperform at BMO Capital
02/24/21 Credit Suisse
Ares Management re-initiated with a Neutral at Credit Suisse
02/12/21 Barclays
Ares Management price target raised to $58 from $56 at Barclays
TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
01/19/21 H.C. Wainwright
Turning Point Therapeutics price target raised to $190 from $130 at H.C. Wainwright
UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

02/18/21 Needham
Ultra Clean price target raised to $55 from $43 at Needham
02/18/21 Craig-Hallum
Ultra Clean price target raised to $69 from $47 at Craig-Hallum
01/29/21 Cowen
Cowen upgrades Ultra Clean to Outperform on robust spending trends
01/29/21 Cowen
Ultra Clean upgraded to Outperform from Market Perform at Cowen
USAT Changed to CTLP
$12.77 /

+0.76 (+6.33%)

02/05/21 Lake Street
USA Technologies price target raised to $12 from $10 at Lake Street
01/06/21 Northland
USA Technologies named a top pick for 2021 at Northland
12/16/20 Northland
Northland upgrades 'recovery story' USA Technologies to Outperform
12/16/20 Northland
USA Technologies upgraded to Outperform from Market Perform at Northland
USAT Changed to CTLP
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

  • 09
    Apr
  • 08
    Apr
  • 06
    Apr
  • 03
    Mar
  • 17
    Feb
  • 29
    Jan
  • 20
    Nov
  • 11
    Nov
  • 27
    Oct
  • 14
    Aug
  • 19
    May
PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

USAT Changed to CTLP
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

USAT Changed to CTLP
$12.77 /

+0.76 (+6.33%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

Hot Stocks
iCAD announces CFO Scott Areglado to leave company » 16:06
04/05/21
04/05
16:06
04/05/21
16:06
ICAD

iCAD

$19.78 /

-0.14 (-0.70%)

iCAD announced that its…

iCAD announced that its CFO Scott Areglado, will be leaving the company in early May to accept a position with another company. An interim CFO will be appointed shortly to serve until such time as a permanent successor to Areglado is in place. The search and selection process for a successor to Areglado is already underway.

ShowHide Related Items >><<
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

ICAD iCAD
$19.78 /

-0.14 (-0.70%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

  • 03
    Mar
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

Earnings
iCAD reports preliminary Q1 revenue $8.1M, consensus $7.89M » 16:04
04/05/21
04/05
16:04
04/05/21
16:04
ICAD

iCAD

$19.78 /

-0.14 (-0.70%)

Unaudited cash and cash…

Unaudited cash and cash equivalents as of March 31, 2021 were approximately $46.9M, which includes proceeds of the public offering closed in March that generated gross proceeds of approximately $25M. "For the first quarter of 2021, anticipated final revenue numbers represent significant growth, compared to the first quarter of 2020," according to Michael Klein, iCAD's chairman and CEO. "Our strong results were driven by growth in both AI Detection revenue, due to continued market penetration for ProFound AI(R) and ProFound AI(R) Risk, and Xoft(R) Therapy revenues."

ShowHide Related Items >><<
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

ICAD iCAD
$19.78 /

-0.14 (-0.70%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

  • 03
    Mar
ICAD iCAD
$19.78 /

-0.14 (-0.70%)

Hot Stocks
iCAD announces results from ProFound AI retrospective analysis » 08:15
03/31/21
03/31
08:15
03/31/21
08:15
ICAD

iCAD

$19.44 /

+0.49 (+2.59%)

iCAD announced that…

iCAD announced that ProFound AI for 2D Mammography might notably reduce the risk of interval breast cancer, according to a retrospective analysis recently published in the Journal of Medical Screening. The aim of the study was to determine if adding AI to reading mammography as a supportive tool may help in decreasing the interval cancer rate in population-based organized mammography screening programs in Germany. In the retrospective analysis, which evaluated a screening period from 2011 and 2012, a total of 37,367 women between the ages of 50-69 were screened with full-field digital mammography. Of these, 29 cases of interval cancers with full documentation were evaluated using ProFound AI for 2D Mammography. For quality assurance, interval cancers with the prior screening mammogram were classified in four categories by the radiologists: true interval cancers, minimal sign cancers, missed cancers based on the original screening exam deemed as normal and dismissed, and occult cancers. The objective of the study was to determine whether ProFound AI for 2D Mammography could identify interval cancers that had either minimal signs in the original normal screening or were missed in the original screening round where they had been dismissed as a normal exam. According to the lead author of the study, Axel Grawingholt, MD, "The results indicate that ProFound AI for 2D Mammography found 93% of these cancers-eight out of nine cancers that presented minimal signs and six out of six that were false negatives, or missed in the screening round-demonstrating that some cancers could have been detected earlier within the screening round where they were dismissed as normal and therefore wouldn't have been detected as interval cancers."

ShowHide Related Items >><<
ICAD iCAD
$19.44 /

+0.49 (+2.59%)

ICAD iCAD
$19.44 /

+0.49 (+2.59%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$19.44 /

+0.49 (+2.59%)

  • 03
    Mar
ICAD iCAD
$19.44 /

+0.49 (+2.59%)

Initiation
iCAD initiated with a Buy at BTIG » 06:20
03/23/21
03/23
06:20
03/23/21
06:20
ICAD

iCAD

$19.35 /

+0.44 (+2.33%)

BTIG analyst Marie…

BTIG analyst Marie Thibault initiated coverage of iCAD with a Buy rating and $25 price target. The analyst is positive on the company's business segments that are looking to expand into areas of "high unmet need" - using AI to help radiologists read mammography images more quickly and accurately and also giving clinicians and patients a more complete picture of the patient's short-term risk of developing breast cancer. Thibault adds that while iCAD's existing products offer "significant revenue opportunity", the company also offers a "full pipeline".

ShowHide Related Items >><<
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

ICAD iCAD
$19.35 /

+0.44 (+2.33%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
02/25/21 Craig-Hallum
iCAD price target raised to $22 from $15 at Craig-Hallum
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

  • 03
    Mar
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

Initiation
iCAD initiated with a Buy at BTIG » 06:01
03/23/21
03/23
06:01
03/23/21
06:01
ICAD

iCAD

$19.35 /

+0.44 (+2.33%)

BTIG analyst Marie…

BTIG analyst Marie Thibault initiated coverage of iCAD with a Buy rating and $25 price target.

ShowHide Related Items >><<
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

ICAD iCAD
$19.35 /

+0.44 (+2.33%)

02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
02/25/21 Craig-Hallum
iCAD price target raised to $22 from $15 at Craig-Hallum
02/25/21 Lake Street
iCAD price target raised to $21 from $17 at Lake Street
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

  • 03
    Mar
ICAD iCAD
$19.35 /

+0.44 (+2.33%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
03/16/21
03/16
08:58
03/16/21
08:58
FTCV

FinTech Acquisition Corp. V

$10.69 /

+0.19 (+1.81%)

, AZRX

AzurRx BioPharma

$1.54 /

+0.18 (+13.24%)

, ICAD

iCAD

$18.75 /

+0.11 (+0.59%)

, JBL

Jabil

$48.90 /

+0.475 (+0.98%)

, DFH

Dream Finders Homes

$26.74 /

-0.14 (-0.52%)

, DBI

Designer Brands

$15.88 /

+0.525 (+3.42%)

, CRH

CRH

$48.34 /

+0.1 (+0.21%)

, AKRO

Akero Therapeutics

$32.91 /

+0.015 (+0.05%)

, FCEL

FuelCell

$17.07 /

-1.09 (-6.00%)

, CLSK

CleanSpark

$29.40 /

-1.5 (-4.85%)

Check out this morning's…

ShowHide Related Items >><<
JBL Jabil
$48.90 /

+0.475 (+0.98%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CRH CRH
$48.34 /

+0.1 (+0.21%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

02/10/21 H.C. Wainwright
AzurRx BioPharma price target raised to $3.50 from $2 at H.C. Wainwright
01/06/21 Dawson James
AzurRx BioPharma downgraded to Neutral from Buy at Dawson James
ICAD iCAD
$18.75 /

+0.11 (+0.59%)

02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
02/25/21 Craig-Hallum
iCAD price target raised to $22 from $15 at Craig-Hallum
02/25/21 Lake Street
iCAD price target raised to $21 from $17 at Lake Street
JBL Jabil
$48.90 /

+0.475 (+0.98%)

12/21/20 Citi
Citi names Dell new to pick for 2021, adds to Focus List
12/18/20 RBC Capital
Jabil price target raised to $44 from $38 at RBC Capital
12/18/20 Citi
Jabil price target raised to $60 from $50 at Citi
12/18/20 JPMorgan
Flex downgraded to Neutral on valuation at JPMorgan
DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

02/18/21 Wedbush
Dream Finders Homes initiated with Neutral at Wedbush on valuation
02/18/21 Wedbush
Dream Finders Homes initiated with a Neutral at Wedbush
02/16/21 BTIG
Dream Finders Homes initiated with a Neutral at BTIG
02/16/21 RBC Capital
Dream Finders Homes initiated with a Sector Perform at RBC Capital
DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

01/21/21 Deutsche Bank
Designer Brands price target raised to $12 from $7 at Deutsche Bank
01/08/21 CL King
Designer Brands named a top pick for 2021 at CL King
11/09/20 UBS
Designer Brands initiated with a Neutral at UBS
11/03/20 Susquehanna
Designer Brands upgraded to Positive from Neutral at Susquehanna
CRH CRH
$48.34 /

+0.1 (+0.21%)

03/10/21 JPMorgan
CRH price target raised to EUR 46 from EUR 43 at JPMorgan
03/09/21 Societe Generale
CRH price target raised to 4,000 GBp from 3,900 GBp at Societe Generale
03/08/21 Barclays
CRH price target raised to EUR 38 from EUR 35 at Barclays
03/08/21 Berenberg
CRH price target raised to EUR 38 from EUR 36 at Berenberg
AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

02/26/21 Guggenheim
Akero Therapeutics initiated with a Buy at Guggenheim
11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

03/05/21 JPMorgan
FuelCell price target lowered to $9 from $10 at JPMorgan
01/22/21 Canaccord
FuelCell price target raised to $15 from $8.50 at Canaccord
01/14/21
Fly Intel: Top five analyst downgrades
01/14/21 JPMorgan
'Richly valued' FuelCell downgraded to Underweight at JPMorgan
CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

03/10/21 BTIG
CleanSpark initiated with a Buy at BTIG
03/10/21 BTIG
CleanSpark initiated with a Buy at BTIG
02/16/21 H.C. Wainwright
CleanSpark price target raised to $50 from $24 at H.C. Wainwright
12/11/20 H.C. Wainwright
CleanSpark price target raised to $24 from $18 at H.C. Wainwright
JBL Jabil
$48.90 /

+0.475 (+0.98%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

  • 16
    Mar
  • 03
    Mar
  • 21
    Jan
  • 02
    Dec
  • 07
    Oct
  • 30
    Sep
  • 08
    Jul
FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

CRH CRH
$48.34 /

+0.1 (+0.21%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

ICAD iCAD
$18.75 /

+0.11 (+0.59%)

FTCV FinTech Acquisition Corp. V
$10.69 /

+0.19 (+1.81%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

DBI Designer Brands
$15.88 /

+0.525 (+3.42%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

AZRX AzurRx BioPharma
$1.54 /

+0.18 (+13.24%)

AKRO Akero Therapeutics
$32.91 /

+0.015 (+0.05%)

FCEL FuelCell
$17.07 /

-1.09 (-6.00%)

DFH Dream Finders Homes
$26.74 /

-0.14 (-0.52%)

CLSK CleanSpark
$29.40 /

-1.5 (-4.85%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.